Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2016

Conditions
Vulvovaginal Candidiasis
Interventions
BIOLOGICAL

NDV-3A

0.5mL injection IM

BIOLOGICAL

NDV-3

0.5mL injection IM

BIOLOGICAL

Placebo

aluminum hydroxide and buffered saline

Trial Locations (20)

11203

SUNY Downstate Medical Center, Brooklyn

11777

Suffolk Ob/Gyn, Port Jefferson

19102

Drexel University College of Medicine, Philadelphia

29752

Magnolia OB/GYN Research Center, LLC, Myrtle Beach

33141

Community Medical Research, Miami Beach

33155

Miami Clinical Research, LLC, Miami

33181

Community Medical Research LLC, North Miami

33316

KO Clinical Research, LLC, Fort Lauderdale

33759

Women's Medical Research Group, LLC, Clearwater

48201

WSU Physician's Group, Detroit

48604

Saginaw Valley Medical Research Group, LLC, Saginaw

70006

MedPharmics, Metairie

72205

Arkansas Women's Center, Little Rock

75231

Discovery Clinical Trials- HCWC, LLC, Dallas

77054

TMC Life Research, Houston

78414

Advanced Research Associates, Corpus Christi

85032

Precision Trials LLC, Phoenix

90505

McCann MD Research, Inc., Torrance

92123

Women's Health Care Research Corp, San Diego

08648

Lawrence OB/Gyn Clinical Research, Lawrenceville

Sponsors
All Listed Sponsors
lead

NovaDigm Therapeutics, Inc.

INDUSTRY

NCT01926028 - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis | Biotech Hunter | Biotech Hunter